Fact Sheet

  • Trikafta is a life-saving, game changing medication that helps 90% of the CF community. This triple combination medication is 3-5X better than the previous medications Orkambi & Symdeko, helping to prevent organ damage and adding years if not decades to the lives of those with CF.
  • Trikafta helps the most common type of CF, the F508del mutation. Trikafta is listed on the PBS for those aged 12+, but more than 500 children aged 6-11 are waiting for access. 
  • Trikafta was developed by Vertex Pharmaceuticals. Studies have showed increased lung function, reduced exacerbations and fewer hospitalisations. Trikafta helps people go back to school, work, have a family and live a longer, healthier life. It helps the young ones to enjoy a healthy childhood with significantly less time unwell and in hospital.
  • Trikafta received a positive recommendation at the November 2022 PBAC meeting, however has gone backwards to the PBAC in March 2023 as negotiations failed.
  • Price $277,875AUD – the high price has placed it out of reach for those with CF. 
  • There were more than 150,000 signatures across several petitions in 2021-2022, showing very strong community support for Trikafta and the need for a faster system in terms of medicine access. 
  • Currently approved in 30 countries for those aged 6-11.
  • Currently half of people with CF pass away by age 37 in Australia – this is why we need urgent access.